Blockchain Registration Transaction Record

VolitionRx Unveils Breakthrough Liquid Biopsy Tech with 99% Pure ctDNA

VolitionRx's Capture-Seq liquid biopsy tech isolates >99% pure ctDNA, enabling early cancer detection and monitoring. Peer-reviewed study published, market potential $23B.

This news matters because it represents a significant advancement in liquid biopsy technology, potentially enabling earlier and more accurate cancer detection and monitoring. If validated in larger studies, Volition's Capture-Seq could lead to non-invasive blood tests that detect multiple cancer types at early stages, improving patient outcomes and reducing healthcare costs. The technology also has implications for minimal residual disease monitoring, which could help guide treatment decisions and detect recurrence earlier. For investors, the potential market opportunities are substantial, with estimates of $23 billion for multi-cancer early detection and $13 billion for minimal residual disease applications. This development could disrupt the current diagnostic landscape and offer new hope for cancer patients worldwide.